pharma news today obesity drugs glp-1 september 2025 2024 was a record year for trials and is already poised to take over GLP-1 RA prescription trends: January

This has no memberships and straight forward

Based on Eli Lilly's public statements and typical FDA timelines, retatrutide approval is most likely in late 2027 or early 2028

Why do these recommendations differ from other published recommendations

Most are once-weekly or daily GLP-1 injectable pens, while Rybelsus is a daily tablet

2022Dysregulated epicardial adipose tissue as a risk factor and potential therapeutic target of heart failure with preserved ejection fraction in diabetes

By separating obesity and diabetes contexts, and by using active comparators like insulin, metformin, and SGLT2 inhibitors, the study attempted to reduce some of the obvious biases that often weaken retrospective analyses